NCT06461533View on ClinicalTrials.gov

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

RecruitingOBSERVATIONAL

Enrollment

25

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Acquired Hemophilia A

Interventions

DRUG

Susoctocog Alfa (Genetical Recombination)

Susoctocog Alfa (Genetical Recombination), Intravenous injection

Trial Locations (1)

Unknown

RECRUITING

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY